A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer

Author:

George Daniel J.12,Halabi Susan23,Heath Elisabeth I.4,Sartor A. Oliver5ORCID,Sonpavde Guru P.6,Das Devika6,Bitting Rhonda L.7,Berry William12,Healy Patrick2,Anand Monika2ORCID,Winters Carol2,Riggan Colleen2,Kephart Julie2,Wilder Rhonda2,Shobe Kellie2,Rasmussen Julia2,Milowsky Matthew I.8ORCID,Fleming Mark T.9,Bearden James10,Goodman Michael11,Zhang Tian12ORCID,Harrison Michael R.12,McNamara Megan12,Zhang Dadong12,LaCroix Bonnie L.2,Kittles Rick A.13,Patierno Brendon M.2,Sibley Alexander B.12,Patierno Steven R.12,Owzar Kouros312,Hyslop Terry23,Freedman Jennifer A.12,Armstrong Andrew J.12ORCID

Affiliation:

1. Department of Medicine, Division of Medical Oncology Duke University Durham North Carolina

2. Center for Prostate and Urologic Cancers Duke Cancer Institute Duke University Durham North Carolina

3. Department of Biostatistics and Bioinformatics Duke University School of Medicine Durham North Carolina

4. Karmanos Cancer InstituteWayne State University Detroit Michigan

5. Tulane Cancer Center Tulane Health Sciences Center New Orleans Louisiana

6. Hematology and Oncology Division Birmingham Veterans Affairs Medical Center Birmingham Alabama

7. Comprehensive Cancer Center Wake Forest University Winston Salem North Carolina

8. Department of Medicine Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina

9. Virginia Oncology Associates Hampton Virginia

10. Gibbs Cancer Center Spartanburg South Carolina

11. W.G. (Bill) Hefner VA Medical Center Salisbury North Carolina

12. Duke Cancer Institute Duke University School of Medicine Durham North Carolina

13. Department of Population Sciences Division of Health Equities City of Hope National Medical Center Duarte California

Funder

Janssen Pharmaceuticals

Prostate Cancer Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference55 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3